BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
about
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.T cell Bim levels reflect responses to anti-PD-1 cancer therapy.Resisting Resistance: Targeted Therapies in Lung Cancer.Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Targeting the Mammalian Target of Rapamycin in Lung Cancer.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyThe IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.Understanding and targeting resistance mechanisms in NSCLC.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.
P2860
Q33566948-C7FCED75-2234-4530-A6AD-E2C759273E99Q36891596-1955929F-C18B-4DA4-864E-A0A39874CB93Q37388238-B2B4EB11-7362-4864-AE4D-54D77DC227A5Q37569995-F65B177B-01B0-45FC-8062-AB69178AF305Q37705651-66754C5A-A507-4FB0-BD3A-C332971A1241Q37741531-7A312F75-D31B-43EF-921C-10E6FC34044AQ38598893-55AE3F0B-2648-4CAA-9FBC-52F355522091Q38879975-C70DDBAC-91C1-43FC-BD52-6097F14981C5Q41471047-3EAE6B2F-BB26-4E1D-8C31-01E2FE56B9F0Q41606248-45387B23-7F53-4A1F-8FB9-9F69D45D0605Q45070526-CDC977C8-04C4-43A7-B550-D41764061FADQ46915997-5214F6DC-5F28-43E1-BAFC-0ECC9E7D5426Q50345931-6BC9518C-C7C6-4460-A080-21DE0F2FDD06Q52332708-D37A0997-1A94-4288-BB93-E290A39BD6F6
P2860
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@ast
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@en
type
label
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@ast
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@en
prefLabel
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@ast
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@en
P2093
P2860
P50
P356
P1433
P1476
BIM and mTOR expression levels ...... ant non-small-cell lung cancer
@en
P2093
Alberto Verlicchi
Ana Drozdowskyj
Ana Giménez-Capitán
Andrés Felipe Cardona
Bartomeu Massuti
Carles Codony-Servat
Daniela Morales-Espinosa
Enric Carcereny
Filippo de Marinis
Guillermo López-Vivanco
P2860
P2888
P356
10.1038/SREP17499
P407
P50
P577
2015-12-07T00:00:00Z